Literature DB >> 8981720

Vision in albinism.

C G Summers.   

Abstract

PURPOSE: The purpose of this investigation was to study vision in albinism from 3 perspectives: first, to determine the characteristics of grating acuity development in children with albinism; second, to study the effect of illumination on grating acuity; and third, to define the effect of melanin pigment in the macula on visual acuity.
METHODS: I. Binocular and monocular grating acuity was measured with the acuity card procedure in 40 children with albinism during the first 3 years of life. Recognition acuity was eventually measured in 27 of these patients. Ocular pigment was documented by a previously established method of grading iris transillumination and macular transparency. II. Grating acuity under standard and increased illumination levels was measured in 20 adults with albinism (group I) compared with that in 20 adults with nystagmus due to conditions other than albinism (group II) and 20 adults without ocular abnormalities (group III). Recognition acuity measured with the ETDRS charts was also recorded for each group. III. Best-corrected binocular acuity was measured in 29 patients with albinism who were identified with melanin pigment in their maculas by direct ophthalmoscopy.
RESULTS: I. Both binocular and monocular grating acuity was reduced 2 to 3 octaves below the norm for ages 6 months to 3 years. Limited data available in the first 6 months of life did not show failure of vision to develop. Grating acuity measurements overestimated eventual recognition acuity. Mean recognition acuity was 20/111. A relationship between grating acuity development and presence or absence of ocular pigment was not found. II. Grating acuity was significantly better for groups I and II under the condition of increased illumination (P < .03). For patients with albinism, grating acuity under standard illumination was significantly better than recognition acuity (P < .001). For all groups, grating acuity under increased illumination was significantly better than recognition acuity (P < .01). III. Mean recognition acuity in patients with albinism and melanin pigment in their maculas (20/47) was significantly better than measured recognition acuity in Project I (P < .001). All had foveal hypoplasia, but 8 patients had an incompletely developed annular reflex in the macula, 6 patients showed stereoacuity, and 3 patients had no nystagmus.
CONCLUSIONS: I. Grating acuity development in albinism seems to progress along a curve that is asymptotic to visual development in a normal population. II. Increasing illumination does not reduce grating acuity in patients with albinism. Grating acuity overestimates recognition acuity in these patients. III. Ophthalmoscopic detection of melanin pigment in the macula in patients with albinism is associated with better vision.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981720      PMCID: PMC1312119     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  215 in total

1.  Quantification of iris translucency in albinism.

Authors:  J D Wirtschafter; G T Denslow; I B Shine
Journal:  Arch Ophthalmol       Date:  1973-10

2.  Effects of normal and aspirin platelets on defective secondary aggregation in the Hermansky-Pudlak syndrome. A test for storage pool deficient platelets.

Authors:  J G White; C J Witkop
Journal:  Am J Pathol       Date:  1972-07       Impact factor: 4.307

3.  Linkage analysis in X-linked ocular albinism.

Authors:  R E Schnur; R L Nussbaum; L Anson-Cartwright; C McDowell; R G Worton; M A Musarella
Journal:  Genomics       Date:  1991-04       Impact factor: 5.736

4.  Ocular findings in the Hermansky-Pudlak syndrome.

Authors:  N J Izquierdo; W Townsend; I E Hussels
Journal:  Trans Am Ophthalmol Soc       Date:  1995

5.  Evaluation of the influence of optic stalk melanin on the chiasmatic pathways in the developing rodent visual system.

Authors:  R J Colello; G Jeffery
Journal:  J Comp Neurol       Date:  1991-03-08       Impact factor: 3.215

6.  Oculocutaneous albinism associated with Apert's syndrome.

Authors:  S Margolis; I M Siegel; A Choy; G M Breinin
Journal:  Am J Ophthalmol       Date:  1977-12       Impact factor: 5.258

7.  Carotenoids in the human macula and whole retina.

Authors:  G J Handelman; E A Dratz; C C Reay; J G van Kuijk
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-06       Impact factor: 4.799

8.  Human albinism. Light and electron microscopy study.

Authors:  A B Fulton; D M Albert; J L Craft
Journal:  Arch Ophthalmol       Date:  1978-02

9.  The retina of the newborn human infant.

Authors:  I Abramov; J Gordon; A Hendrickson; L Hainline; V Dobson; E LaBossiere
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

10.  Operant acuity of toddlers and developmentally delayed children with low vision.

Authors:  E Birch; L Hale; D Stager; D Fuller; D Birch
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1987 Mar-Apr       Impact factor: 1.402

View more
  25 in total

1.  Visual acuity development of children with infantile nystagmus syndrome.

Authors:  Valeria L N Fu; Richard A Bilonick; Joost Felius; Richard W Hertle; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-14       Impact factor: 4.799

2.  Behavioral and genetic color vision evaluation of an albino male capuchin monkey (Sapajus apella).

Authors:  Leonardo Dutra Henriques; J C P Oliveira; D M O Bonci; R C Leão; G S Souza; L C L Silveira; O F Galvão; P R K Goulart; D F Ventura
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2019-05-20       Impact factor: 1.836

3.  Relationship between foveal cone specialization and pit morphology in albinism.

Authors:  Melissa A Wilk; John T McAllister; Robert F Cooper; Adam M Dubis; Teresa N Patitucci; Phyllis Summerfelt; Jennifer L Anderson; Kimberly E Stepien; Deborah M Costakos; Thomas B Connor; William J Wirostko; Pei-Wen Chiang; Alfredo Dubra; Christine A Curcio; Murray H Brilliant; C Gail Summers; Joseph Carroll
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-20       Impact factor: 4.799

4.  Arrested development: high-resolution imaging of foveal morphology in albinism.

Authors:  John T McAllister; Adam M Dubis; Diane M Tait; Shawn Ostler; Jungtae Rha; Kimberly E Stepien; C Gail Summers; Joseph Carroll
Journal:  Vision Res       Date:  2010-02-10       Impact factor: 1.886

5.  Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.

Authors:  Ighovie F Onojafe; David R Adams; Dimitre R Simeonov; Jun Zhang; Chi-Chao Chan; Isa M Bernardini; Yuri V Sergeev; Monika B Dolinska; Ramakrishna P Alur; Murray H Brilliant; William A Gahl; Brian P Brooks
Journal:  J Clin Invest       Date:  2011-10       Impact factor: 14.808

6.  Clinical Insights Into Foveal Morphology in Albinism.

Authors:  Brandon K McCafferty; Melissa A Wilk; John T McAllister; Kimberly E Stepien; Adam M Dubis; Murray H Brilliant; Jennifer L Anderson; Joseph Carroll; C Gail Summers
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2015 May-Jun       Impact factor: 1.402

Review 7.  Pigmentation and vision: Is GPR143 in control?

Authors:  Brian S McKay
Journal:  J Neurosci Res       Date:  2018-05-14       Impact factor: 4.164

8.  MC1R mutations modify the classic phenotype of oculocutaneous albinism type 2 (OCA2).

Authors:  Richard A King; Rebecca K Willaert; Ramona M Schmidt; Jacy Pietsch; Sarah Savage; Marcia J Brott; James P Fryer; C Gail Summers; William S Oetting
Journal:  Am J Hum Genet       Date:  2003-07-22       Impact factor: 11.025

Review 9.  Adaptation of the central retina for high acuity vision: cones, the fovea and the avascular zone.

Authors:  Jan M Provis; Adam M Dubis; Ted Maddess; Joseph Carroll
Journal:  Prog Retin Eye Res       Date:  2013-03-15       Impact factor: 21.198

10.  Imaging of the Functional and Dysfunctional Visual System.

Authors:  Edgar A DeYoe; John L Ulmer; Wade M Mueller; David S Sabsevitz; Danielle C Reitsma; Jay J Pillai
Journal:  Semin Ultrasound CT MR       Date:  2015-05-27       Impact factor: 1.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.